Fig. 4.

PTPN3 inhibition increases the cytotoxicity against cancer cells in vivo. a–f Therapy experiments using allo-activated lymphocytes targeting SUIT-2 cells from healthy volunteers are shown. Allo-activated lymphocytes transfected with control shRNA or PTPN3#2 shRNA were administered at 6, 9, 13, and 16 days after tumor injection (arrows in b). a Representative photos of formed tumors. b The tumor volume at the indicated days and c Kaplan–Meier plot of the tumor growth are shown. d The tumor weight at 22 days after tumor injection was assessed. e Representative photos of immunohistochemical staining of CD8 in formed tumors. Original magnification ×200. f The numbers of labeled tumor-infiltrating-administrated lymphocytes (TILs) were counted. g–l Therapy experiments using tumor and autologous lymphocytes from a patient with ovarian cancer are shown. Autologous-activated lymphocytes transfected with control shRNA or PTPN3#2 shRNA were administered at 11, 14, 18, and 21 days after tumor injection (arrows in h). g Representative photos of formed tumors. h The tumor volume at the indicated days and i Kaplan–Meier plot of the tumor growth are shown. j Representative photos of immunohistochemical staining of CD3 in formed tumors. Original magnification ×200. k The numbers of non-tumor-tissue-infiltrating-administrated lymphocytes (ntTILs) were counted. l The numbers of ntTILs in the spleen, liver and lung were counted. Data are presented as the mean ± SD. *p < 0.05